MS-20 on Gut Microbiota and Risk/Severity of Cachexia in Pancreatic Cancer Patients
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Cachexia has been recognized as a direct cause of reduced quality of life complicating in
cancer patients. Patients with pancreatic cancer have the highest prevalence in developing
severe degrees of cachexia. Providing supportive therapies for these patients may provide a
lot of benefit on overarching quality of life and improve overall survival.
MS-20 is indicated for treating the symptom of fatigue and loss of appetite induced by
chemotherapy in cancer patients. According to the result from pre-clinical study, MS-20 may
have potential to attenuate or suppress the resistant phenomena of chemotherapy via
alternating gut microbiota profile.
In this study, MS-20 effects on on gut microbiota and risk/severity of cachexia will be
analyzed in pancreatic cancer patients who under combination therapy with chemotherapy and
MS-20.